Up to 24% body-weight reduction at 48 weeks in the published Phase 2 trial. Triple-agonist of GLP-1, GIP, and glucagon receptors.
Body-weight reduction at 48 weeks per the published Phase 2 trial
Receptor agonist (GLP-1, GIP, glucagon)
Roughly what we charge vs. US compounding pharmacies
Retatrutide is a triple-agonist peptide — it activates three different receptors that control hunger, energy expenditure, and fat metabolism. In Eli Lilly's published Phase 2 trial (Jastreboff et al., NEJM 2023), the highest-dose group lost an average of 24.2% of body weight at 48 weeks. That's roughly double Wegovy and meaningfully more than Tirzepatide at the same time point in their respective trials.
It's still investigational — not FDA-approved as of May 2026. Lilly's Phase 3 is in progress. We sell it as a research compound, and you make your own decision about what to do with it.
We're not screening you. You're an adult. But please read this before ordering and please talk to a doctor if anything below applies to you.
Adults who've read the published trial data. People who've tried other GLP-1s and are exploring stronger options. People working with their own doctor on a weight-management plan. People who understand titration and have a way to source bacteriostatic water and syringes.
You have a personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome. You have active pancreatitis or gallbladder disease. You're pregnant or breastfeeding. You have severe kidney impairment. You're new to GLP-1s and haven't talked to a doctor.
Drawn directly from the Jastreboff et al. NEJM 2023 paper. Real individual outcomes vary. Talk to your doctor about titration.
Appetite suppression typically starts within the first week of titration. Mild nausea is common and usually resolves.
Average 6–10% body-weight loss by week 12 at standard titration in the trial cohort.
12–18% body-weight loss range in the trial. Body composition shifts.
Phase 2 mean at the highest dose was 24.2% body weight reduction at 48 weeks.
Wegovy hits one receptor (GLP-1). Tirzepatide hits two (GLP-1 + GIP). Retatrutide hits three (GLP-1 + GIP + glucagon). The glucagon arm is what's thought to unlock additional fat oxidation — and likely why the weight-loss numbers in the Phase 2 trial came out so much higher.
From the published Phase 2 trial. Most are GI-related and resolve with slow titration. Talk to your doctor about how to manage them.
Nausea (~40% at high dose) · Diarrhea · Constipation · Vomiting · Decreased appetite (that's the point) · Fatigue in week 1–2
Tachycardia · Elevated blood pressure · Severe GI symptoms requiring a dose hold · Allergic reactions (rare)
Call your local emergency services first. Then contact your own doctor. We're a peptide supplier, not a medical provider — we can't manage adverse events for you. Please don't use this without a way to get medical care if you need it.
Roughly what we charge vs. US compounding pharmacies.
Supplier certificate of analysis shared with every order on request.
From payment confirmation to ship-out, within Colombia.
You're not just buying a vial. You get the complete system — what to buy, how to reconstitute, how to store, where to inject, how to dose, and exactly what to eat alongside it. The stuff every other vendor leaves you to figure out alone.
Explore The PlaybookOne molecule, two vial sizes. Pay, we ship. Nothing tied to a consultation or subscription.
$500.000 COP
10mg lyophilized · Supplier COA shared · Cold-chain shipping within Colombia included
$900.000 COP
20mg lyophilized · Better $/mg for ongoing use · Same COA and shipping
Retatrutide is investigational and not FDA-approved as of May 2026. Medellin Peptides.co sells research-grade peptides for adult buyers in Colombia. We are not a clinic and do not provide medical care, prescriptions, or treatment. Cited weight-loss percentages reference Jastreboff et al., 2023 (NEJM) Phase 2 trial data; individual results vary and we make no guarantee of outcome. Not for use in pregnancy, breastfeeding, MTC/MEN2 family history, severe renal impairment, or active pancreatitis. Please consult a qualified healthcare professional before use.